Thrombospondin-1 as a paradigm for the development of antiangiogenic agents endowed with multiple mechanisms of action

Marco Rusnati, Chiara Urbinati, Silvia Bonifacio, Marco Presta, Giulia Taraboletti

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Uncontrolled neovascularization occurs in several angiogenesis-dependent diseases, including cancer. Neovascularization is tightly controlled by the balance between angiogenic growth factors and antiangiogenic agents. The various natural angiogenesis inhibitors identified so far affect neovascularization by different mechanisms of action. Thrombospondin-1 (TSP-1) is a matricellular modular glycoprotein that acts as a powerful endogenous inhibitor of angiogenesis. It acts both indirectly, by sequestering angiogenic growth factors and effectors in the extracellular environment, and directly, by inducing an antiangiogenic program in endothelial cells following engagement of specific receptors including CD36, CD47, integrins and proteoglycans (all involved in angiogenesis). In view of its central, multifaceted role in angiogenesis, TSP-1 has served as a source of antiangiogenic tools, including TSP-1 fragments, synthetic peptides and peptidomimetics, gene therapy strategies, and agents that up-regulate TSP-1 expression. This review discusses TSP-1-based inhibitors of angiogenesis, their mechanisms of action and therapeutic potential, drawing our experience with angiogenic growth factor-interacting TSP-1 peptides, and the possibility of exploiting them to design novel antiangiogenic agents.

Original languageEnglish
Pages (from-to)1241-1278
Number of pages38
JournalPharmaceuticals
Volume3
Issue number4
DOIs
Publication statusPublished - 2010

Fingerprint

Thrombospondin 1
Angiogenesis Inhibitors
Angiogenesis Inducing Agents
Intercellular Signaling Peptides and Proteins
Peptidomimetics
Peptide Fragments
Proteoglycans
Integrins
Genetic Therapy
Action Potentials
Glycoproteins
Up-Regulation
Endothelial Cells
Peptides
Neoplasms

Keywords

  • Angiogenesis
  • Integrins
  • Interactions
  • Thrombospondin-1
  • Tumor

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Thrombospondin-1 as a paradigm for the development of antiangiogenic agents endowed with multiple mechanisms of action. / Rusnati, Marco; Urbinati, Chiara; Bonifacio, Silvia; Presta, Marco; Taraboletti, Giulia.

In: Pharmaceuticals, Vol. 3, No. 4, 2010, p. 1241-1278.

Research output: Contribution to journalArticle

Rusnati, Marco ; Urbinati, Chiara ; Bonifacio, Silvia ; Presta, Marco ; Taraboletti, Giulia. / Thrombospondin-1 as a paradigm for the development of antiangiogenic agents endowed with multiple mechanisms of action. In: Pharmaceuticals. 2010 ; Vol. 3, No. 4. pp. 1241-1278.
@article{00ac6e76bacc4695b81bcd779d1c7127,
title = "Thrombospondin-1 as a paradigm for the development of antiangiogenic agents endowed with multiple mechanisms of action",
abstract = "Uncontrolled neovascularization occurs in several angiogenesis-dependent diseases, including cancer. Neovascularization is tightly controlled by the balance between angiogenic growth factors and antiangiogenic agents. The various natural angiogenesis inhibitors identified so far affect neovascularization by different mechanisms of action. Thrombospondin-1 (TSP-1) is a matricellular modular glycoprotein that acts as a powerful endogenous inhibitor of angiogenesis. It acts both indirectly, by sequestering angiogenic growth factors and effectors in the extracellular environment, and directly, by inducing an antiangiogenic program in endothelial cells following engagement of specific receptors including CD36, CD47, integrins and proteoglycans (all involved in angiogenesis). In view of its central, multifaceted role in angiogenesis, TSP-1 has served as a source of antiangiogenic tools, including TSP-1 fragments, synthetic peptides and peptidomimetics, gene therapy strategies, and agents that up-regulate TSP-1 expression. This review discusses TSP-1-based inhibitors of angiogenesis, their mechanisms of action and therapeutic potential, drawing our experience with angiogenic growth factor-interacting TSP-1 peptides, and the possibility of exploiting them to design novel antiangiogenic agents.",
keywords = "Angiogenesis, Integrins, Interactions, Thrombospondin-1, Tumor",
author = "Marco Rusnati and Chiara Urbinati and Silvia Bonifacio and Marco Presta and Giulia Taraboletti",
year = "2010",
doi = "10.3390/ph3041241",
language = "English",
volume = "3",
pages = "1241--1278",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Thrombospondin-1 as a paradigm for the development of antiangiogenic agents endowed with multiple mechanisms of action

AU - Rusnati, Marco

AU - Urbinati, Chiara

AU - Bonifacio, Silvia

AU - Presta, Marco

AU - Taraboletti, Giulia

PY - 2010

Y1 - 2010

N2 - Uncontrolled neovascularization occurs in several angiogenesis-dependent diseases, including cancer. Neovascularization is tightly controlled by the balance between angiogenic growth factors and antiangiogenic agents. The various natural angiogenesis inhibitors identified so far affect neovascularization by different mechanisms of action. Thrombospondin-1 (TSP-1) is a matricellular modular glycoprotein that acts as a powerful endogenous inhibitor of angiogenesis. It acts both indirectly, by sequestering angiogenic growth factors and effectors in the extracellular environment, and directly, by inducing an antiangiogenic program in endothelial cells following engagement of specific receptors including CD36, CD47, integrins and proteoglycans (all involved in angiogenesis). In view of its central, multifaceted role in angiogenesis, TSP-1 has served as a source of antiangiogenic tools, including TSP-1 fragments, synthetic peptides and peptidomimetics, gene therapy strategies, and agents that up-regulate TSP-1 expression. This review discusses TSP-1-based inhibitors of angiogenesis, their mechanisms of action and therapeutic potential, drawing our experience with angiogenic growth factor-interacting TSP-1 peptides, and the possibility of exploiting them to design novel antiangiogenic agents.

AB - Uncontrolled neovascularization occurs in several angiogenesis-dependent diseases, including cancer. Neovascularization is tightly controlled by the balance between angiogenic growth factors and antiangiogenic agents. The various natural angiogenesis inhibitors identified so far affect neovascularization by different mechanisms of action. Thrombospondin-1 (TSP-1) is a matricellular modular glycoprotein that acts as a powerful endogenous inhibitor of angiogenesis. It acts both indirectly, by sequestering angiogenic growth factors and effectors in the extracellular environment, and directly, by inducing an antiangiogenic program in endothelial cells following engagement of specific receptors including CD36, CD47, integrins and proteoglycans (all involved in angiogenesis). In view of its central, multifaceted role in angiogenesis, TSP-1 has served as a source of antiangiogenic tools, including TSP-1 fragments, synthetic peptides and peptidomimetics, gene therapy strategies, and agents that up-regulate TSP-1 expression. This review discusses TSP-1-based inhibitors of angiogenesis, their mechanisms of action and therapeutic potential, drawing our experience with angiogenic growth factor-interacting TSP-1 peptides, and the possibility of exploiting them to design novel antiangiogenic agents.

KW - Angiogenesis

KW - Integrins

KW - Interactions

KW - Thrombospondin-1

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=77952203693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952203693&partnerID=8YFLogxK

U2 - 10.3390/ph3041241

DO - 10.3390/ph3041241

M3 - Article

AN - SCOPUS:77952203693

VL - 3

SP - 1241

EP - 1278

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 4

ER -